新華醫療(600587.SH)2020年淨利預降66.18%-85.92%
格隆匯1月29日丨新華醫療(600587.SH)披露2020年度業績預減公吿,預計2020年度實現歸屬於上市公司股東的淨利潤與上年同期8.61億元相比,將減少5.70億元到7.40億元,同比減少66.18%到85.92%;歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期-2934.69萬元相比,將增加1.44億元到2.02億元。
公司此次業績預減主要是由於上年同期非經常性損益事項金額較大所致,具體為:2019年,公司對威士達醫療有限公司實施了重組、出售了蘇州長光華醫生物醫學工程有限公司8.2041%的股權,公司投資收益額度較大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.